A push to ramp up production of successful COVID-19 vaccines, continued demand for effective COVID-19 treatments, and an increased focus on other critical, non-COVID diseases are driving growth in the biotech industry – and against this backdrop, the author of today’s article highlights four particular biotech stocks that should see significant growth in the coming months. For these four stocks,…
While the author of today’s article acknowledges that, “Of course, it can be challenging for investors to navigate around the complexities that come with the biotech industry,” he advises that, “with proper research and due diligence, investors could make educated guesses on which biotech stocks to bet on.” So which biotech stocks are worth watching heading into June? For the…
“These are five stocks for aggressive investors looking to get share count leverage on biotech companies that have sizable upside potential,” says the author of today’s article of the five biotech stocks he highlights – all of which are trading under the $10 level and are rated “Overweight” at Oppenheimer. For these five biotech stocks, CLICK HERE.
“A big, headline-grabbing company is not always your best bet, assuming you’re a shrewd investor seeking to maximize your profits,” advises the author of today’s article – and this may be especially true when it comes to biotech stocks. What two “size benefits” do smaller companies have – and why does the “size factor” work? CLICK HERE.
The pharmaceutical company featured in today’s article, known for its innovative drug pipeline, is a late-stage biotech focused on developing novel, oral, small-molecule drugs for rare and serious diseases. Having gained 153.8% over the past year and 60.1% year-to-date, is this a good biotech stock to own? For a look at the factors that could influence its performance in the near…
The prospect of tighter regulation of the sector (particularly when it comes to mergers and drug approvals) and drug-pricing reform, as well as rising interest rates, have created a “perfect storm” bearing down on biotech stocks. As a result, after seeing massive gains in 2020, biotech stocks have pulled back. Do biotech investors have reason to worry, or is biotech’s…
“The kinds of biotechs best for investors who aren’t huge risk-takers are those that generate solid revenue growth, are profitable (or soon will be), and have promising pipelines,” advises the author of today’s article, who proceeds to highlight three stocks that appear to match this profile to consider buying this month. For more, CLICK HERE.
A rumored takeover candidate is among the five small-cap biotech stocks trading under $10 highlighted in today’s article, all of which boast Buy ratings from well-known Wall Street firms – and solid upside potential. For these five biotech stocks, which are suited for very aggressive investors, CLICK HERE.
“These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential,” says the author of today’s article of the five stocks he highlights – all of which have Buy ratings at major firms and are trading under the $10 level. For these five stocks –which include an intriguing biotech play with…
With new leadership at the federal agencies that oversee the drug industry, a top Wall Street analyst is warning that the biotech industry and biotech investors “will need to adjust to a different regulatory environment to the one they have enjoyed for the last 5 years” – and has downgraded six pharma stocks due, in part, to the prospect of…